#no vaccine for 40 crore in india

[soignerpharmaindia]

Top 10 pharmaceutical companies in Hyderabad

Top 10 pharmaceutical companies in Hyderabad: Are You New to the Pharma Business and Looking to Invest in the Best? Discover High-Margin Profits Here. Stop Googling “Best PCD Pharma Franchise in Hyderabad” because you're in the right place! Hyderabad, the “Pharma Hub of India,” is the ideal destination for anyone looking to make a mark in the pharmaceutical industry. This city is the hub of most reputable medicine companies that not only offer quality products but also genuine business opportunities with high-margin profits. If you're aiming for success, partnering with the listed Top 10 Pharma Companies in Hyderabad 2024 For Business. Known for their product quality, respected positions in the market, and proven track records, these companies are the giants of Hyderabad's pharma industry.

Soigner Pharma 

Welcome To Soigner Pharma, a proud ISO and GMP-certified Best PCD Pharma Franchise Company in Hyderabad 2024 that deals in DCGI approved  low-cost but high-quality medicines. They offer the best franchise business opportunity to dedicated and interested entrepreneurs with unique monopoly rights. You can join them at low capital investment and enjoy high margin profit.

Established: 2007

CEO: Umesh Karla

Number of Products: 1000+

Pharma Range: Tablets, Capsules, Injections, Syrup, Sachet, Protein Powder, Ointment, Cream, Drops, Soap, Gel

Global Presence: Over 5 countries

Employees: 100+

Connected Entrepreneurs: Over 500+

Address: Sco-6, Near Sunpark Hotel, Wadhwa Nagar, Sas Nagar., Zirakpur- 140603, Punjab, India

Dr. Reddy's Laboratories

One of the Top 10 Pharma Companies in Hyderabad 2024 For Business, Dr Reddy’s Labortories is famous for its high-quality medicine list and franchise business opportunities in Hyderabad. They offer the best support to linked entrepreneurs.

Established: 1984

CEO: Erez Israeli

Global Presence: Over 50 countries

Revenue (FY 2023): ₹25,000 crores (approx.)

Employees: 21,650+

Address: 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034, Telangana, India

Aurobindo Pharma

Aurobindo Pharma, a well-known PCD Pharma Franchise company in Hyderabad famous for its genuine business opportunity. They go along with ethical business module to run business smoothly in the pharma industry.

Established: 1986

CEO: N. Govindarajan

Global Presence: Over 150 countries

Revenue (FY 2023): ₹24,774 crores (approx.)

Employees: 23,000+

Address: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500038, Telangana, India

Divi's Laboratories

Established: 1990

CEO: Murali K. Divi

Global Presence: Products in over 95 countries

Revenue (FY 2023): ₹8,960 crores (approx.)

Employees: 16,500+

Address: 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad - 500032, Telangana, India

Gland Pharma

Established: 1978

CEO: Srinivas Sadu

Global Presence: Major presence in the U.S., Europe, India

Revenue (FY 2023): ₹4,970 crores (approx.)

Employees: 4,000+

Address: Sy. No. 143-148, Near Gandimaisamma ‘X’ Roads, D.P. Pally, Dundigal, Hyderabad - 500043, Telangana, India

Granules India

Established: 1984

CEO: Krishna Prasad Chigurupati

Global Presence: 300+ customers across 60 countries

Revenue (FY 2023): ₹3,540 crores (approx.)

Employees: 8,000+

Address: 2nd Floor, Block III, My Home Hub, Madhapur, Hyderabad - 500081, Telangana, India

Biological E. Limited

Established: 1953

CEO: Mahima Datla

Global Presence: Vaccines distributed in over 100 countries

Revenue (FY 2023): ₹2,500 crores (approx.)

Employees: 5,000+

Address: 18/1 & 3, Azamabad, Hyderabad - 500020, Telangana, India

Hetero Drugs

Established: 1993

CEO: B. Parthasaradhi Reddy

Global Presence: Over 126 countries

Revenue (FY 2023): ₹8,000 crores (approx.)

Employees: 21,000+

Address: 7-2-A2, Industrial Estate, Sanath Nagar, Hyderabad - 500018, Telangana, India

Natco Pharma

Established: 1981

CEO: Rajeev Nannapaneni

Global Presence: Products in over 40 countries

Revenue (FY 2023): ₹2,200 crores (approx.)

Employees: 5,000+

Address: Natco House, Road No. 2, Banjara Hills, Hyderabad - 500034, Telangana, India

Shanta Biotechnics (A Sanofi Company)

Established: 1993

Founder: Dr. K. I. Varaprasad Reddy (Sanofi acquired Shanta)

Global Presence: Focus on emerging markets

Revenue (FY 2023): ₹500 crores (approx.)

Employees: 1,000+

Address: Medchal Mandal, Qutubullapur Municipality, Hyderabad - 500054, Telangana, India

[charcha-equity]

Abhay Bhutada Foundation: Innovating Community Health in India

The Abhay Bhutada Foundation (ABF), founded by Abhay Bhutada, stands ready to significantly impact community health in India. With a strong foundation in finance and a commitment to using technology for good, Bhutada aims to revolutionize community health with innovative and sustainable solutions.

Abhay Bhutada: A Visionary in Leadership

Abhay Bhutada, the Founder and Chairman of the Abhay Bhutada Foundation, also serves as the Non-Executive Director on the Board of Poonawalla Fincorp Limited (PFL). Born and raised in Latur, Maharashtra, Bhutada graduated in Commerce from Symbiosis International University in 2005 and became a Chartered Accountant in 2009. His career began in 2010 as an SME Finance Professional with the Bank of India, quickly demonstrating his entrepreneurial talents and leadership abilities.

Bhutada, a former Managing Director of Poonawalla Fincorp, has received numerous accolades, including "Young Entrepreneur of India 2017," "Promising Entrepreneur of India 2019," and "40 under 40 Most Influential Leader for 2020-21." His dedication to corporate social responsibility, particularly in healthcare and education, laid the groundwork for ABF.

Also Read: Next Steps for Poonawalla Fincorp After Abhay Bhutada’s Shift to Non-Executive Director

The Abhay Bhutada Foundation: Mission and Vision

Incorporated on July 28, 2023, the Abhay Bhutada Foundation is a private not-for-profit organization based in Pune, Maharashtra. Its mission is to improve community health outcomes by addressing healthcare needs in underserved populations. With an authorized and paid-up capital of Rs 1.00 crore, ABF is positioned to fund and implement significant health initiatives.

Directors Narayan Jarange and Sujit Thite collaborate with Bhutada to ensure ABF's objectives are achieved. The foundation is classified under Business Activity Class/Subclass Code 88, emphasizing its focus on health and social work activities.

Also Read: Abhay Bhutada Foundation: A Commitment to Social Welfare

Technology in Health

Abhay Bhutada's vision of enhancing financial services through technology extends to his work with the Abhay Bhutada Foundation. ABF aims to make healthcare more accessible and efficient by leveraging digital tools and innovative solutions, particularly in rural and remote areas where healthcare infrastructure is lacking.

A key initiative of ABF is the development of telemedicine services, connecting patients with healthcare providers and reducing the need for travel. The foundation also plans to implement health information systems for better patient data tracking and health outcome monitoring.

Community Health Programs

The Abhay Bhutada Foundation is dedicated to addressing various health issues affecting communities across India. Key initiatives include:

Preventive Healthcare Programs: ABF organizes health camps, vaccination drives, and awareness campaigns on hygiene and nutrition to reduce chronic disease incidence.

Maternal and Child Health: ABF prioritizes the health of mothers and children, providing prenatal and postnatal care, along with educational programs for expecting and new mothers.

Mental Health Support: Recognizing mental well-being's importance, ABF offers mental health services, including counseling and support groups.

Health Infrastructure Development: ABF invests in building and upgrading healthcare facilities in underserved areas, including setting up clinics, providing medical equipment, and training healthcare workers.

Also Read: Abhay Bhutada Foundation and Its Mission for Social Change

The Future of Community Health

Under Abhay Bhutada's leadership, the Abhay Bhutada Foundation is poised to play a pivotal role in transforming community health in India. By combining innovative technology with a compassionate approach, ABF aims to create sustainable health solutions benefiting millions.

As Bhutada assumes a strategic role at the Cyrus Poonawalla Group, his commitment to improving healthcare through the foundation remains steadfast. His involvement in industry forums such as CII, ASSOCHAM, FICCI, and FIDC amplifies his dedication to driving positive change in healthcare.

Conclusion

The Abhay Bhutada Foundation represents a beacon of hope for communities in need of better healthcare. With Abhay Bhutada's visionary leadership and a dedicated team, ABF is well-prepared to address community health challenges and pave the way for a healthier future. By leveraging technology and focusing on preventive care, maternal and child health, mental health support, and infrastructure development, the foundation is set to make a lasting impact on countless individuals' well-being across India.

[foxnangelseo]

Wadia Group's Investment in Go First Signals Confidence in India's Aviation Sector Growth

Go First, formerly known as GoAir, is a low-cost airline based in Mumbai, India. The airline is owned by the Wadia Group, one of India's oldest and largest conglomerates. In a recent announcement, the Wadia Group has revealed that it plans to invest 300 crore rupees (approximately $40 million) in Go First over the next few months.

According to reports, the investment will be used to fund the airline's expansion plans, including the acquisition of new aircraft and the launch of new routes. Go First currently operates a fleet of 40 aircraft, including Airbus A320neo and A320ceo models, and serves over 30 domestic and international destinations.

The Wadia Group's investment comes at a time when the aviation industry in India is slowly recovering from the impact of the COVID-19 pandemic. Like many airlines around the world, Go First was severely affected by the pandemic, with passenger traffic dropping significantly due to travel restrictions and reduced demand.

However, with the rollout of vaccination programs and the easing of restrictions, the airline industry in India is slowly regaining momentum. Go First is well-positioned to take advantage of this recovery, with its focus on low-cost, no-frills travel that appeals to budget-conscious travelers.

In addition to the investment, the Wadia Group has also announced that it is looking for a strategic partner for Go First. The partnership is expected to help the airline expand its network and improve its operational efficiency, as well as provide access to new sources of capital.

The search for a strategic partner is part of the Wadia Group's broader efforts to diversify its business interests and focus on growth opportunities in key sectors. The conglomerate has a long history of successful investments in industries such as textiles, chemicals, and real estate, and has recently been looking to expand into new areas such as e-commerce and fintech.

The Wadia Group's investment in Go First is also a reflection of the growing importance of the aviation sector in India's economy. With a population of over 1.3 billion people, India is a vast and diverse country that is increasingly connected through air travel. The growth of low-cost airlines such as Go First has helped to democratize air travel in India, making it more accessible to a wider range of people.

However, the aviation industry in India still faces a number of challenges, including high fuel prices, regulatory hurdles, and infrastructure constraints. The search for a strategic partner for Go First is therefore a smart move, as it will help the airline to navigate these challenges and stay ahead of the competition.

In conclusion, the Wadia Group's investment in Go First is a positive development for the airline industry in India, as it signals renewed confidence in the sector's growth prospects. With the help of a strategic partner, Go First is well-positioned to expand its network, improve its operational efficiency, and continue to offer affordable air travel to millions of passengers in India and beyond.

This post was originally published on: Foxnangel

[takataktop]

Chandramukhi 2 Box Office Day 4: Clash Continues Between 'Chandramukhi 2' and 'Fukrey 3', This Film Earns More on Sunday

Chandramukhi 2 continues to shine at the box office, giving tough competition to 'The Vaccine War' and 'Fukrey 3'. The horror-comedy movie, which was originally made in the Tamil and Telugu languages, is performing exceptionally well in India and worldwide. Let's take a look at the total earnings of this film so far.

Chandramukhi 2 Box Office Day 4: Kangana Ranaut, who couldn't make a big impact with her last film 'Dhaakad' at the Indian box office, has struck gold with her latest movie 'Chandramukhi 2'. In this film, she plays the role of Chandramukhi for the first time, alongside Raghav Lawrence. The audience has showered their love on Kangana Ranaut's portrayal of Chandramukhi in the movie. In just four days, this film has earned around 40 crore worldwide. Let's find out how 'Chandramukhi 2' performed at the Indian and worldwide box office on Sunday. Impressive Earnings in All Languages: Kangana Ranaut's film faced tough competition at the box office from Varun Sharma and Pulkit Samrat's 'Fukrey 3' and 'The Vaccine War'. However, 'Chandramukhi 2', released not only in Hindi but also in Tamil and Telugu languages, has given a tough fight to 'Fukrey 3', especially in the Hindi language. Girish Johar shared the information on his Twitter account, revealing that 'Chandramukhi 2' is performing exceptionally well at the Tamil box office. In just four days, the Kangana-Raghav starrer has earned more than 40 crore. In the Hindi language alone, the film has collected a net income of 29 crore after Sunday. Impressive Performance in Tamil and Telugu: 'Chandramukhi 2' is making waves in the Tamil language as well, starting with 5 crore and earning 5.17 crore on the fourth day. In the Telugu language, the film has earned a total of 1.07 crore. Total 4 Days Collection of 'Chandramukhi 2': - Worldwide Box Office Collection: 41 crore rupees - Hindi Box Office Net Collection: 29 crore rupees - Tamil Box Office Collection: 18.2 crore rupees / Single Day: 5.17 crore - Telugu Box Office Collection: 5.32 crore rupees / Single Day: 1.07 crore - Hindi Box Office Gross Collection: 20 crore rupees - Overseas Collection: 12 crore rupees 'Chandramukhi 2' has crossed the 18.2 crore mark in Tamil and 5.32 crore in Telugu. According to reports, 'Chandramukhi 2', which has earned 29 crore in Hindi, has also collected 12 crore rupees overseas. As of Sunday, the film has a total collection of 41 crore worldwide. Read the full article

[mediwinpharma]

The New Leap of Indian Pharma Export in FY23

Introduction

Pharma companies have seen significant growth in the industry, and technological advancement and growing demand are the main factors for this growth. The new rules are helping the industry, and new technology is making it easier to sell medicine. Indian medicine is known for being of good quality and for being innovative, so the future looks good for Indian medicine sales.

This blog will explore the growth of medicine export from India, the factors for the growth of top Indian pharma export companies, and their impact on the economy.

Factors Contributing to the Growth of the Pharmaceutical Industry in India

Here are some pointers explaining the factors briefly.

1. Government Initiatives to Boost Pharma Export

Some initiatives taken by the government to boost the pharma export are as follows:

In March 2022, the government announced the strengthening of the pharmaceutical industry (SPI) scheme with a total budget of 500 crores for FY 2021-22 to FY 2025-26.

After a hiatus, India resumed deliveries of COVID-19 shots to the COVAX program in November-December

In November 2021, Prime Minister Narendra Modi launched the inaugural Global Innovation Summit for the pharmaceutical industry. The summit will consist of 12 sessions with more than 40 speakers from both national and international backgrounds discussing various topics such as regulations, financing for innovation, and infrastructure for innovation.

The Department of Pharmaceuticals has launched a PLI (Production Linked Incentive) scheme to promote domestic manufacturing of essential bulk drugs to achieve self-sufficiency and reduce the country���s dependence on imports. The total cost of the scheme will be 6,940 crores and will be implemented between FY21 and FY30.

2. Investment in R&D and innovation

Research and development (R&D) are important in every industry. It is particularly essential in the biopharmaceutical research sector. It helps to save lives and increase profits. Developing new vaccinations and therapies is becoming increasingly difficult. Reliable R&D services can help pharmaceutical enterprises follow manufacturing methods, leading to the creation of numerous new medications.

In 2015, the industry spent Rs. 6,02,388 crore on R&D for novel medicines. The approval process for these export medicines can be lengthy, but the number of successful approvals determines the businesses’ ability to recoup their investment and profit.

3. Globalization

When India opened its socialist economy and began trading globally, big pharma exporters from the US and Europe entered the Indian market. They set up cheaper and more efficient production facilities offshore to reduce costs and expand their operations. This created opportunities for small-scale industries to grow their products. The entry of big pharma companies into the Indian market allowed smaller businesses to expand, create more opportunities, and export pharmaceutical products worldwide.

4. Quality and Compliance

Quality and compliance are crucial to India’s growth in the pharmaceutical industry. With the rising pharmaceutical sector, all companies must follow strict quality standards to ensure their products are safe. This led to more investment in research and development and better manufacturing processes.

By applying such factors, India’s pharmaceutical industry is recognized for producing high-quality products that follow international standards, which attracts more business and investment globally. This way, India can export medicines in a more accessible way.

Impact of the Growth of Pharmaceutical Companies on the Economy

The growth of India has had a significant impact on the country’s economy. Here are some ways in which the pharma exporters have contributed to the economy:

1. Improved Healthcare Access

The pharmaceutical industry in India has been growing rapidly. The government is helping more people afford healthcare and medicine by making them cheaper. India needs to have its medical industry so it doesn’t depend too much on China. Therefore, India is making plans to produce more medicine inside the country.

These plans are called “production-linked incentive” (PLI) schemes. The PLI schemes give money to Indian companies to help them make more medicine and medical equipment. The PLI schemes have been working well so far. In the last two years, nearly Rs. 16,435 crore has been given to 55 companies to help them make medicine.

2. Job Creation and Economic Benefits

A pharma exporter plays an important role in the Indian economy. Top Indian pharma export companies employ around 2.7 million people directly to the firm. It also creates employment through the supply chain.

The pharmaceutical sector also contributes to the country’s economic growth by generating revenue and promoting medicine export from India, a leading pharma exporter.

The government of India took several initiatives to promote the sector, including allocating funds for research and development, boosting domestic manufacturing, and promoting innovation to increase medicine export from India.

3. Increased Revenue and Growth for the Indian Pharma Industry

The pharmaceutical industry in India is a significant player in the global market. Here are some reasons why:

The Indian pharmaceutical industry is ranking third in production by volume and 14th by value.

From April 2000 and June 2022, foreign investment in India’s drugs and pharmaceutical industry was around $19.90 billion.

Cipla and Drugs for Neglected Diseases initiative (DNDi) teamed up to launch a new medicine in June 2022 to treat HIV in children in South Africa.

The Union Cabinet has approved FDI up to 100% under the automatic route for manufacturing medical devices subject to certain conditions.

In August 2021, Uniza Group signed an agreement with Lysulin Inc. to introduce Lysulin, a nutritional product for Indian consumers.

How can Pharmaceutical Companies Leverage the New Leap?

Pharmaceutical companies can leverage the new leap in various ways to expand their business and make a mark in the global market. Here are a few pointers:

1. Maximize Efficiency

Production efficiency refers to achieving output goals with minimal input. Collecting data from various areas makes it possible to identify improvement areas. Automation can also reduce the manual input, time, and resources required to complete tasks.

Efficiency can also be improved by the convergence of information technology (IT) and operational technology (OT) through the use of Industrial Internet of Things (IIoT) technology. It allows for data collected from production to inform business decisions. Efficient communication between IT and OT is facilitated by a common structure for data exchange.

2. Improve Industrial Security

Pharmaceutical companies can face cyberattacks and security threats, which can cause them to hesitate to adopt new technologies that could improve productivity. However, implementing these technologies while safeguarding against security risks can provide a competitive advantage.

Having a strong cybersecurity system and using technologies with top-notch built-in security features is crucial. COPA-DATA has received a certificate of conformity from TÜV SÜD, which verifies compliance with the industrial IT security standards outlined in the ISA/IEC 62443-4-1:2018 guidelines.

3. Simplify Operation Workflows

The pharmaceutical industry has strict quality requirements at every step of the process. The common batch process can be beneficial, but it also means that one error can lead to a ruined batch, wasted resources, and potentially serious consequences. Effective batch control is crucial to avoid these negative scenarios.

Pharmaceutical manufacturers must collect and manage process data to ensure the quality of exported pharmaceutical products. However, relying on paper documentation can lead to errors. Automating data collection with mobile devices can improve efficiency and reduce the likelihood of mistakes. This way, you can export medicines without committing errors.

4. Better Production

Efficiency in pharmaceutical manufacturing can also be improved by increasing machinery life and uptime. Equipment breakdowns and underperformance can cost companies money in terms of repairs, lost production time, and damaged batches of products. Investing in high-quality equipment and implementing an effective maintenance program can help export pharmaceutical products more efficiently.

Predictive maintenance programs can be more efficient than fixed or reactive schedules because they allow companies to forecast when maintenance is needed based on data collected from the sensors. This helps companies avoid unnecessary maintenance work and detect signs of future failures before they cause downtime or high repair costs.

Conclusion

Based on the information, it can be expected that the Indian pharmaceutical company will witness a considerable surge in export growth during FY23. The pharmaceutical company’s growth can be attributed to healthcare expansion and growing research and development. By doing all this, India is now a global lead player that export pharmaceutical products to all nations.

Mediwin Phayrmaceuticals has a unique opportunity to leverage its commitment to quality and innovation to emerge as a dominant player in the industry. Mediwin will capture a substantial portion of the expanding global market and has the potential to become one of the top Indian pharma export companies in the global market.

Source link

[delhinewsinenglish]

Active Covid cases in country decline to 37,444

India logged 3,375 new coronavirus infections taking the total tally of COVID-19 cases to 4,45,94,487, while the active cases declined to 37,444, according to the Union Health Ministry data updated on Sunday.

The death toll climbed to 5,28,673 with 18 fatalities which includes 11 deaths reconciled by Kerala, the data updated at 8 am stated.

The active cases comprise 0.08 per cent of the total infections, while the national COVID-19 recovery rate increased to 98.73 per cent, the ministry said.

A decline of 849 cases has been recorded in the active COVID-19 caseload in a span of 24 hours.

The daily positivity rate was recorded at 1.28 per cent while the weekly positivity rate was recorded at 1.35 per cent, according to the ministry.

The number of people who have recuperated from the disease surged to 4,40,28,370, while the case fatality rate was recorded at 1.19 per cent.

According to the ministry, 218.75 crore doses of Covid vaccine have been administered in the country so far under the nationwide vaccination drive.

India's COVID-19 tally had crossed the 20-lakh mark on August 7, 2020, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16. It went past 60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, 90 lakh on November 20 and surpassed the one-crore mark on December 19.

The country crossed the grim milestone of two crore on May 4 and three crore on June 23 last year. It crossed the four-crore mark on January 25 this year.

The seven fatalities reported in the last 24 hours include three from Maharashtra and one each from Kerala, Odisha, Tamil Nadu and West Bengal.

[tezlivenews]

भारत में 100 करोड़ का जश्‍न, 40 करोड़ ऐसे भी जिन्‍होंने नहीं लगवाई वैक्‍सीन की एक भी डोज

भारत में 100 करोड़ का जश्‍न, 40 करोड़ ऐसे भी जिन्‍होंने नहीं लगवाई वैक्‍सीन की एक भी डोज

नई दिल्‍ली. भारत ने कोविड वैक्‍सीनेशन में 100 करोड़ वैक्‍सीन की डोज लगाने का लक्ष्‍य प्राप्‍त कर लिया है. 9 महीने में हासिल की गई इस उपलब्धि पर देशभर में जश्‍न मनाया जा रहा है. हालांकि सरकारों की तमाम कोशिशों और जागरुकता अभियानों के बावजूद एक बड़ी संख्‍या ऐसी भी है जिसने कोरोना वैक्‍सीन की पहली डोज भी नहीं लगवाई है. भारत में 40 करोड़ व्‍यस्‍कों ने अभी तक कोरोना टीके की एक भी खुराक नहीं ली है, यह…

[unique-live]

4,800 Covid Cases In India, 18 Virus-Related Death In 24 Hours

New Delhi: With 4,858 new coronavirus infections being reported in a day, India's tally of COVID-19 cases rose to 4,45,39,046, while the active cases increased to 48,027, according to the Union Health Ministry data updated on Monday. The death count has climbed to 5,28,355 with 18 fatalities, which includes eight deaths reconciled by Kerala, the data updated at 8 am stated.

The active cases comprise 0.11 per cent of the total infections, while the national COVID-19 recovery rate has increased to 98.71 per cent, the health ministry said. An increase of 105 cases has been recorded in the active COVID-19 caseload in a span of 24 hours, it said.

The daily positivity rate was recorded at 2.76 per cent, while the weekly positivity rate was at 1.78 per cent, according to the health ministry.

The number of people who have recuperated from the disease surged to 4,39,62,664, while the case fatality rate was 1.19 per cent. According to the ministry, 216.70 crore doses of vaccines have been administered in the country so far under the nationwide COVID-19 vaccination drive.

India's COVID-19 tally had crossed the 20-lakh mark on August 7, 2020, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16

[worldwideanalysis]

With 1 in 12 People Suffering from Asthma, Demand for Air Purifiers Rising Globally

The rise in air pollution is one of the main concerns for environmentalists and chronic respiratory disease (CRD) patients. According to the Environmental Protection Agency of the U.S., the pollutant concentration in indoor air can be five times higher than in outside air, due to limited air circulation in buildings, thus resulting in the growth of airborne pollutants. Over 500 million people are affected by chronic respiratory diseases each year as a result of fossil fuel burning and poor indoor air circulation adoption rate.

The most-common CRDs are asthma, occupational lung diseases, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension. Patients are always at a high risk of complications due to a rise in air pollution levels, lifestyle habits, such as tobacco smoking; occupational dust and chemical exposure, and a childhood history of frequent lower respiratory infections.

According to CDCP, one in every twelve people suffer from asthma. Therefore, in 2021, the air purifier market stood at $11,422.7 million, and it is expected to advance at a rate of 11.8% from 2021 to 2030, to reach $31,195.6 million. These devices mitigate indoor air pollutants that lead to respiratory infections and other complications in asthma patients. Air purifiers with the high-efficiency particulate air (HEPA) technology can eliminate 99.7% of the airborne particulate matter circulating in the indoor environment.

In present times, the rising prevalence of COVID-19, with the emergence of different variants with high transferability, is making governments across the world take concrete actions to save lives. Vaccination has been effective. but there is always a risk of COVID-19 infection. Hence, a lot of people have bought air purifiers for homes and offices to shield themselves and others from the virus.

Since the virus transmits across people through nasal droplets that stay suspended in the air, the risk increases in indoor spaces with no or ineffective ventilation. The most-effective step to reduce COVID-19 risk is wearing a mask, but nobody can wear one the entire day. Thus, the installation of an air purifier can be the second line of defense against the pathogen.

Similarly, other indoor air pollutants, such as the fumes of incense, camphor, and cooking gas, may also cause respiratory diseases and asthma exacerbation. Using HEPA air purifiers can result in long-term health benefits, such as improved life expectancy and enhanced sleep quality, for asthma and other CRD patients.

This is why people around the world, especially in China, India, and other highly polluted countries, have started installing such appliances in their homes. Moreover, governments in these countries are facing increasing flak from citizens for the deteriorating air quality, especially in the Delhi–NCR region of India. The Indian capital is notorious for its bad air, with a severe AQI not uncommon anymore.

Therefore, the Delhi government has installed two massive smog towers in the city, which are essentially extra-large air purifiers, to clean up the air. Each 24-meter-high tower has 5,000 HEPA air filters and 40 large fans, which together purify 1,000 cubic meters of air each second. Moreover, INR 12.5 crore more has been directed by the Delhi High Court to be spent on another smog tower.

Thus, the growing prevalence of CRDs has resulted in an increasing demand for air purifiers to mitigate the spread of airborne particles carrying infectious agents.

[optimistictigercomputer]

COVID-19: India's positivity rate past 1% again after 2 months

he rise reported on Monday pushed the country's overall Covid tally to 4,30,82,345 cases and 5,23,869 deaths, the health ministry data said. India's Covid case positivity rate went past one per cent again after over two months as the country witnessed a single-day rise of 3,157 infections and 26 fatalities, according to the Union Health Ministry data updated on Monday.

The rise reported on Monday pushed the country's overall Covid tally to 4,30,82,345 cases and 5,23,869 deaths, the data said.

The number of active cases rose by 408 in a 24-hour span to reach 19,500, the data updated at 8 am showed. At 1.07 per cent, the daily positivity went past one per cent again after a little over two months, the ministry said. It was at 1.11 per cent on February 27. The weekly positivity rate was 0.70 per cent, according to the health ministry. Positivity rate refers to percentage of all coronavirus tests performed that return positive result. A higher positive rate means higher transmission rate for the virus. The death toll has now climbed to 5,23,869 with the latest 26 fatalities being reported, 21 of them from Kerala alone. The active cases constitute 0.05 per cent of the total infections. The country's COVID-19 recovery rate was recorded at 98.74 per cent, the health ministry said.The number of people who have recuperated from the disease rose to 4,25,38,976, while the case fatality rate was recorded at 1.22 per cent. The cumulative doses administered in the country so far under the nationwide COVID-19 vaccination drive has exceeded 189.23 crore. India's COVID-19 tally had crossed the 20-lakh mark on August 7, 2020, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16. It surpassed the one-crore mark on December 19.

India crossed the grim milestone of two crore on May 4 and three crore on June 23.

The 26 new fatalities include 21 from Kerala, two from Odisha and one each from Karnataka, Uttar Pradesh and West Bengal.

A total of 5,23,869 deaths have been reported so far in the country including 1,47,843 from Maharashtra, 69,068 from Kerala, 40,102 from Karnataka, 38,025 from Tamil Nadu, 26,175 from Delhi, 23,508 from Uttar Pradesh and 21,202 from West Bengal. The health ministry stressed that more than 70 per cent of the deaths occurred due to comorbidities.

[anudip]

Why Should Schools Be Reopened?

COVID-19 has caused immense suffering to people with both lives and economies impacted. No sector has remained unaffected from this pandemic that does not recognize borders and infects people through droplets dispersed in the air. One of the sectors to have faced the brunt of the pandemic is education. The pandemic has forced schools, colleges, universities, or for that matter skill development centers, such as those run by Anudip, a non-profit organization established in 2007, to close and shift to the internet.

For close to two years, children all across India and abroad were not able to go to their schools as authorities, for the fear of the contagion, chose to keep the gates of all educational institutions shut. However, now, with most children and educators continuing to leverage the online medium to study, isn’t it time to switch back to the original medium - of studying in physical classrooms? With the spread of the pandemic waxing and waning as new waves threaten humanity from time to time, a lot of water has flown down the bridge during the two years. 

Even though online learning has continued with its share of issues, not every child has benefited from it. The stark digital divide in India where a large number of students do not have access to the internet or internet-enabled devices has forced them out of the education system. According to a survey by Pratichi Trust, about 40% of students in the primary sections in Kolkata could not attend online classes due to the absence of the internet and the unavailability of smart devices. The picture is verily similar in other states as well. With the future of a large number of students at stake, and the ebbing of the impact of the pandemic, isn’t it time to reopen the schools? Let us discuss the reasons in the segment below: 

Why should schools be reopened - top reasons?  

The prolonged closure of schools has led to the loss of learning among students. According to UNESCO, staying away from school every month results in a loss of learning for 2 months. Also, as per the analysis of the Asian Development Bank, each year of lost schooling leads to an equivalent earning deficiency of 9.7% in the future. Thus, studying at home did not quite lead to any substantive progress in learning with socially disadvantaged groups faring the worst in performance. 

Children are naturally protected: Since children do not have developed receptors in their lungs (the Angiotensin Conversion Enzyme II of ACE-II receptors), which the virus uses to enter the lungs, children have fewer chances of contracting severe COVID-19. In Sweden, there has been no child mortality from COVID-19 even though the schools were kept open during the peak of the pandemic. Importantly, according to a joint statement by UNICEF and UNESCO in July 2021, for any pandemic-based restrictions, schools should be the last to be closed. 

Online learning, a poor substitute for in-person classes: There is plenty of evidence to show that remote schooling or virtual learning has a negative impact on the learning abilities of children. They miss out on holistic learning such as behavioral and social skills, which they learn while interacting with other children in schools. Moreover, with schools closed, around 12 crore children from socially disadvantaged groups are not getting their nutritional needs fulfilled. 

Digital divide: Not every child in India has access to a smart device to pursue online learning. For them, the closure of schools has dealt a body blow to their educational pursuits with many of them getting sucked into social vices like child labor or marriage. 

Conclusion The governments in India have been reluctant to reopen schools due to the fear of children and teachers contracting the virus. However, the apprehensions are unfounded as the chances of children getting severe COVID are rare. Besides, vaccination of children should not be a precondition for opening schools. In most countries around the world, children are attending schools without being vaccinated. Based on the above considerations, it is clear that the cost of not studying in-person in schools is far greater than the fear of contracting COVID.

[speakerreetywadhwa]

    Requested Ministry-wise PIB releases.

    Requested Ministry-wise PIB releases.

Press Information Bureau Government of India •India’s Cumulative COVID-19 Vaccination Coverage exceeds 170.21 Cr •Rs. 3.22 lakh crore sanctioned under PMMY against target of Rs. 3.50 lakh crore in FY 2020-21 •More than 71 lakh subscribers enrolled under Atal Pension Yojana upto 24.01.2022 •Progress related to PM Gati Shakti National Master Plan •Besides Ministry of Tribal affairs, 40 Central…

[newsupdatesbykiara]

India records over 83,500 fresh Covid-19 cases, 895 more deaths

India on Monday reported 83,876 fresh COVID-19 cases that took its total tally to 4,22,72,014, according to Union health ministry data.

The death toll climbed to 5,02,874 with 895 more fatalities, the data updated at 8 am stated.

The number of active cases in the country declined further to 11,08,938, comprising 2.62 per cent of the total infections. The national COVID-19 recovery rate improved to 96.19 per cent, the ministry said.

A reduction of 1,16,073 cases has been recorded in the active COVID-19 caseload in a span of 24 hours.

The daily positivity rate was recorded at 7.25 per cent, while the weekly positivity rate was recorded at 9.18 per cent, the ministry said.

The number of people who have recuperated from the disease surged to 4,06,60,202, while the case fatality rate stands at 1.19 per cent, it said.

The cumulative doses administered in the country so far under the nationwide COVID-19 vaccination drive have exceeded 169.63 crore.

India's COVID-19 tally had crossed the 20-lakh mark on August 7, 2020, 30 lakh on August 23, 40 lakh on September 5 and 50 lakh on September 16. It went past 60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, 90 lakh on November 20 and surpassed the one-crore mark on December 19.

[sterlingheights]

The impact of Coronavirus on the Indian real estate and what is in it for the homebuyers

In our country, the real estate sector has been the second-biggest source of employment, the first being the agriculture sector. It is estimated that the real estate sector in India is expected to cross US$ 1 trillion in market size by 2030, with a contribution of 13% to the country’s GDP by 2025.

According to current government estimates, by the year 2051, around 88 crore people are going to be living in urban areas of India, a whopping 91% increase from the present 46 crores. This will lead to a substantial increase in demand for residential real estate.

While the long-term story seems to remain intact, the onslaught of the Coronavirus pandemic and resulting series of local, regional, and national lockdowns between March and June 2020 severely impacted the nation’s economy. When the country was trying to limp back to some revival mode came the second wave, seemingly far more severe. The real estate sector, especially in big cities like Hyderabad, was severely affected, with new construction coming to an abrupt standstill due to the mass migration of labour to survive. The industry experts believe that the recovery will depend on how India deals with the Coronavirus and carries out the mass vaccination program.

The scale of impact as it stands

Going by a report from India Ratings (Ind-Ra), while the overall residential demand declined by over 40 percent in H1 of FY21, the new project launches across India increased by 71 percent between January and June 2021.

Whatever the current scenario is, developers believe that the sector is better prepared. The pandemic has made one thing clear: it is time to plan for the short term rather than the future due to uncertainty within the market.

Here are four reasons which come as a relief for real estate developers and are beneficial for home buyers:

1. Gradually firming up of prices

Demand and supply have shown signs of recovery, albeit slow, with new property prices going up in cities like Hyderabad by as much as 5% compared to the same time last year.

2. Actual buyers: For residence, not investment

With work from home becoming the order of the day, families started spending more time together. The pent-up demand for residential real estate from home buyers for actual residential purposes and not just for investment or realty value appreciation came to the fore, providing relief to the real estate sector.

3. Attractive home loan interest rates

Homebuyers are regaining confidence within the realty sector despite the Covid-19 pandemic-related slowdown. Amid the RBI continuing to remain the repo rate unchanged at 4%, homebuyers can get home loans for as low as 6.65% annual interest compared to eight seen in January 2020.

4. Buy properties from wherever you are

Like all other industries, the real estate sector saw a big wave of digital adoption both by the developer and the buyer, going beyond the usual websites and videos to try & recreate the immersive experience of exploring a residential property! This has helped in faster, smarter scouting, shortlisting, and finally buying properties from the comfort & safety of wherever the buyer is.

Finally…

The ongoing pandemic has and will continue to impact different parts of the real estate ecosystem differently. The human and sectoral resilience aided by favourable governmental policies and positive consumer sentiment is expected to help put the past behind and move forward with much optimism.

Sterling Heights premium open plots in Hyderabad presents an ideal destination to build your dream homes, and for many others, it’s a lucrative investment option. For more details, log onto www.sterlingheights.in or call 63663 70422. Today!

[reportodisha]

Precaution Dose For Healthcare And Frontline Workers From 10th January; PM

December 26

Precaution Dose From 10th January

Addressing the Nation on Saturday, Prime Minister announced that from 3rd January 2022, Monday, vaccination ( Precaution Dose ) will start for the children in the age group of 15-18 years. The move is likely to aid in education normalization in schools and will reduce the worry of the parents with school going children. He also announced precaution dose for healthcare and frontline workers from 10th January 2022, Monday. This has been done in the light of the amount of time that the frontline workers and health care workers spend in the service of Covid patients. In India, this has been called ‘precaution dose’ not booster dose. The decision of precaution dose will strengthen confidence of healthcare and front-line workers. The Prime Minister also announced that option of precaution dose will be available for senior citizens above 60 years of age with co-morbidity on the advice of their doctors from 10th January, 2022. Referring to the Omicron infections In India, the Prime Minister requested the people not to panic and to follow precautions such as masks and washing hands repeatedly. The Prime Minister said that the global experience of fighting the pandemic has told that following all guidelines is the biggest weapons in the fight against Corona. Second weapon is vaccination, he said. The Prime Minister informed that the vaccination campaign started on 16th January this year has crossed the mark of 141 crore doses. He credited the collective efforts of the citizens, scientists and health workers and doctors for this success. The seriousness of vaccine was identified very early and along with research on vaccine, work was focussed on approval process, supply chain, distribution, training, IT support system and certification, he said. Due to these efforts, 61 percent of the adult population of the country has received both the vaccines and 90 percent adults have received one dose. The Prime Minister emphasized that today, as the virus is mutating, our capability and confidence to face the challenge is also multiplying along with our innovative spirit. He informed that today the country has 18 lakh isolation beds, 5 lakh oxygen supported beds, 1 lakh 40 thousand ICU beds, 90 thousand ICU and Non ICU beds specially for children, more than 3 thousand PSA oxygen plants, 4 lakh oxygen cylinders and  support to states is being provided for buffer doses and testing. The Prime Minister assured that soon the country will develop nasal vaccine and the world’s first DNA vaccine. The Prime Minister emphasized that India’s fight against Corona has, from the very beginning, based on scientific principles, scientific consultation and scientific method. 11 Month vaccine campaign, the Prime Minister said, has brought relief and normalcy in the everyday lives of the countrymen. Economic activities have been encouraging compared to many countries of the world. However, the Prime Minister cautioned that Corona has not gone and alertness is of paramount importance. Shri Modi also cautioned against the efforts to spread rumours, confusion and fear. He appealed to strengthen the speed up the world’s biggest vaccination campaign in the coming days. Stay tuned for more updates... Read the full article